NCT07096336Recruiting
Effect of Vitamin D3 on Brain Waves in Male Parkinson's Patients With Low Vitamin D: A qEEG Study
Effect of Vitamin D3 Supplementation on Brain Waves in Male Parkinson's Disease Patients With Hypovitaminosis D : A Quantitative Electroencephalogram Analysis
Source: ClinicalTrials.gov · Last updated 31 Jul 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This is an experimental study (Interventional self-controlled trial, pretest-posttest design). The goal of this clinical trial is to evaluate the effect of vitamin D3 supplementation on quantitative EEG in male Parkinson's disease patients with hypovitaminosis D. The main question it aims to answer is: Vitamin D3 supplementation has effect on brain waves in male Parkinson's disease patients with hypovitaminosis D. Researcher will compare the effect of vitamin D3 supplementation on brain waves in male Parkinson's disease patients with hypovitaminosis D with their pre intervention ( baseline ) condition on brain waves to assess whether there will be any improvement of brain electrical activity by quantitative electroencephalogram (QEEG). Participants will : Take vitamin D3 orally for 8 weeks (50,000 IU/week) Visit the medical university after 8 weeks for evaluation of serum 25(OH)D level and QEEG Must bring the empty strips of vitamin D supplement with them during their visit.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 15 (estimated)
- First submitted
- 15 Jul 2025
- Start date
- 15 Jul 2025
- Primary completion date
- 30 Nov 2025
- Lead sponsor
- Bangladesh Medical University
- Diseases
- Parkinson disease
- NCT number
- NCT07096336
What you commit to
- Study type: Interventional
- Planned participants: 15
- From 15 Jul 2025 to the primary completion date, 30 Nov 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Current use of medication/substances known to affect neuronal excitability or EEG patterns, such as - sedatives, antidepressant, antipsychotics, alcohol.
Other illness
- Patients who are currently suffering from following diseases
- Neurological disorders (Migraine, epilepsy)
- Cardiovascular disorders (Myocardial infarction, hypertension, cardiac arrhythmia, heart failure)
- Respiratory disorders (Bronchial asthma, COPD)
- Psychiatric illness (e.g., schizophrenia, major depression, bipolar disorder, severe dementia)
- With biochemical evidence of-
- Hypercalcemia
- Renal insufficiency
- Liver diseases
- Endocrine disorders (uncontrolled diabetes mellitus, Hypothyroidism, Hyperthyroidism)
Other
- Already taking vitamin D3 supplements
- Active smoker
Who the study is looking for
- Male Patients with PD up to stage 3 according to Hoehn and Yahr (H-Y) scale
- Age: 51years to70 years
- BMI: 18.5-24.9 kg/m2
- Hypovitaminosis D (Serum 25(OH)D level \<30 ng/ml)
- Patients on Levodopa therapy
Age in the registry: 51 years to 70 years · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Bangladesh Medical University Coordinator of this site? Confirm its status | Dhaka | Bangladesh | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.